ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

Showing results for NIH/NCI

November 22, 2019

Congress passed another continuing resolution (CR) on November 21 – the second CR since the start of the fiscal year (FY) on October 1. The CR provides flat funding for government agencies through December 20 to avoid a government shutdown and gives Congress more time to come to an agreement on a final FY 2020 appropriations package.

Short-term spending bills make it difficult for the National Institutes of Health (NIH) – as well as the institutions and scientists it supports – to effectively plan for research projects.  

November 12, 2019

Norman “Ned” Sharpless, MD, returned to his post of Director of the National Cancer Institute (NCI) earlier this month. Dr. Sharpless had been serving as Acting Commissioner of the Food and Drug Administration (FDA) since Dr. Scott Gottlieb stepped down in April 2019.

Earlier this month, President Trump announced his nomination of Dr. Stephen Hahn to serve as the new Commissioner of the FDA. Admiral Brett Giroir, MD, will serve as Acting Commissioner of the FDA until a permanent commissioner is confirmed by the Senate.

October 30, 2019

ASCO’s Government Relations Committee Chair-elect, Carolyn Hendricks, MD, FASCO, spoke at a congressional briefing organized by the One Voice Against Cancer coalition about the importance of federal funding in making progress against cancer. ASCO also recently urged the leaders of the House and Senate Appropriations Committees to quickly enact a FY 2020 funding bill that includes robust, sustained funding for the NIH.

October 1, 2019

On September 30, President Trump signed into law a Continuing Resolution (CR), which would provide flat funding for federal agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI), through November 21, 2019. ASCO encourages Congress to take action to include the highest increase possible in a full Fiscal Year (FY) 2020 funding package.

September 26, 2019

The National Cancer Institute (NCI) is sponsoring a quarterly webinar series honoring the legacy of Arti Hurria, MD, in improving the treatment of older adults with cancer. The first webinar titled, Perspectives on Cancer and Aging: Arti Hurria Memorial Webinar Series, will be held on October 7, 2019, from 1:00-2:00 pm ET. 

July 23, 2019

A new report from the National Cancer Institute (NCI), produced in collaboration with ASCO, details the scale and breadth of global oncology activities conducted around the world by 70 NCI-designated cancer centers.

May 9, 2019

ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.

April 11, 2019

ASCO submitted testimony to the U.S. House and Senate Appropriations Committees urging them to increase funding for the National Institutes of Health, National Cancer Institute, and Food and Drug Administration.

April 2, 2019

ASCO joined the Alliance for Childhood Cancer on Capitol Hill for the 8th Annual Childhood Cancer Action Day, where advocates met directly with Members of Congress and their staff about cancer policy priorities related to pediatric cancer.

During the Action Day, advocates urged Members of Congress to:

April 1, 2019

Today, ASCO is kicking off its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft FY 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).

March 27, 2019

ASCO joined hundreds of other patient groups, scientific societies, and research and health care institutions in urging members of Congress to increase federal funding for cancer research and prevention in the Fiscal Year (FY) 2020 funding bill.

March 12, 2019

"We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS)." 

February 13, 2019

On February 12, 2019, ASCO leadership and members of the society’s Government Relations Committee met with representatives from key federal agencies, advisory groups, and other stakeholder organizations to discuss top cancer policy priorities. The meetings focused on access to clinical trials, drug pricing, step therapy, drug shortages, Medicaid waivers and other issues affecting people with cancer.

January 9, 2019

A new global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes will help inform the understanding of cancer risk. Wendy Rubinstein, MD, PhD, FACP, FACMG, and Deputy Medical Director of CancerLinQ, LLC, a wholly owned nonprofit subsidiary of ASCO, served as a co-author of the new paper published this week in PLOS Genetics detailing the development of the new resource, BRCA Exchange.